CGON CG Oncology
- 33.890
- +0.160+0.47%
CG Oncology News
Express News | CG Oncology Initiates Expanded Access Program For Cretostimogene Grenadenorepvec In The US In Non-Muscle Invasive Bladder Cancer Patients Who Are Unresponsive To Bacillus Calmette-Guerin
Express News | CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec
Foresite Capital Raises $900M to Invest in Healthcare and Life Science Startups at All Stages
SAN FRANCISCO--(BUSINESS WIRE)--#lifesciences--Foresite Capital, a multi-stage healthcare and life sciences investment firm with more than $3.5 billion under management, announced today that it has cl
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Science Applications International Corporation (NASDAQ:SAIC) declined 11% to $119.91 following first-quarter results.SAIC reported a 9% revenue decline year over year in the fiscal first qua
Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Monday.Shares of Stericycle, Inc. (NASDAQ:SRCL) rose sharply during Monday's session after the company inked a deal to be
Analysts Are Bullish on Top NA Stocks: Viking Holdings Ltd (VIK), CG Oncology, Inc. (CGON)
Viking, CRISPR, Intellia Among Potential M&A Targets: Wells Fargo
Sector Update: Health Care Stocks Softer in Friday Afternoon Trading
Health care stocks were easing Friday afternoon, with the NYSE Health Care Index down 0.2% and the Health Care Select Sector SPDR Fund (XLV) decreasing 0.1%. The iShares Biotechnology ETF (IBB) rose 0
CG Oncology Says Potential Combination Therapy for Bladder Cancer Meets Phase 2 Primary Endpoint
CG Oncology (CGON) said Friday that its phase 2 trial of cretostimogene plus pembrolizumab to treat BCG-unresponsive high-risk non-muscle invasive bladder cancer with carcinoma in situ met its primary
Express News | CG Oncology To Present Final Results From Phase 2 CORE-001 Study Of Cretostimogene Grenadenorepvec In Combination With Pembrolizumab In BCG-Unresponsive High-Risk NMIBC At ASCO 2024 Annual Meeting
CG Oncology to Present Positive Final Results From Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination With Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting
CG Oncology, Inc. (NASDAQ: CGON) today announced final results from the Phase 2 CORE-001 clinical trial of its oncolytic immunotherapy candidate, cretostimogene, in combination with pembrolizumab for the treatment of BCG-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) with Carcinoma in Situ (CIS).
Decoding 10 Analyst Evaluations For CG Oncology
In the latest quarter, 10 analysts provided ratings for CG Oncology (NASDAQ:CGON), showcasing a mix of bullish and bearish perspectives.The following table provides a quick overview of their recent ra
CG Oncology Price Target Raised to $50.00/Share From $43.00 by Goldman Sachs
CG Oncology Price Target Raised to $50.00/Share From $43.00 by Goldman Sachs
Goldman Sachs Upgrades CG Oncology to Buy From Neutral With $50 Price Target
CG Oncology (CGON) has an average outperform rating and a price target range of $50 to $86, according to analysts polled by Capital IQ.
CG Oncology Raised to Buy From Neutral by Goldman Sachs
CG Oncology Raised to Buy From Neutral by Goldman Sachs
Express News | Goldman Sachs Upgrades CG Oncology to Buy, Announces $50 Price Target
CG Oncology Expects Cash Runway to Be Sufficient to Fund Ops Through 2027 >CGON
CG Oncology Expects Cash Runway to Be Sufficient to Fund Ops Through 2027 >CGON
Express News | CG Oncology Inc Q1 Shr View $-0.32 -- Lseg Ibes Data
Express News | CG Oncology Inc - Qtrly Shr Loss $0.36
CG Oncology 1Q Loss/Shr 36c >CGON
CG Oncology 1Q Loss/Shr 36c >CGON
Analysis
Price Target
No Data
